Tempest Therapeutics Inc. (TPST)
NASDAQ: TPST
· Real-Time Price · USD
6.57
-0.22 (-3.24%)
At close: May 14, 2025, 3:55 PM
6.66
1.37%
After-hours: May 14, 2025, 07:32 PM EDT
-3.24% (1D)
| Bid | 6.36 |
| Market Cap | 24.01M |
| Revenue (ttm) | 486K |
| Net Income (ttm) | -41.84M |
| EPS (ttm) | -19.5 |
| PE Ratio (ttm) | -0.34 |
| Forward PE | -4.17 |
| Analyst | Hold |
| Ask | 7.22 |
| Volume | 67,613 |
| Avg. Volume (20D) | 56,191 |
| Open | 6.66 |
| Previous Close | 6.79 |
| Day's Range | 6.34 - 6.79 |
| 52-Week Range | 5.36 - 47.45 |
| Beta | -2.21 |
About TPST
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TPST
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TPST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
-10.47%
Tempest Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
9 months ago
+30.25%
Tempest Therapeutics shares are trading higher after the company announced feedback from its end-of-Phase 2 meeting with the FDA for amezalpat in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma.
